Drug Trial Radar · NCT05463744
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Last checked: Nov 20, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
692
Actual
Start
Aug 12, 2022
Primary completion
May 7, 2024
Study completion May 7, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
Conditions
- Type 1 Diabetes
- Diabetes
Interventions
Insulin Efsitora AlfaDrug
Administered SC
Insulin DegludecDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 [Noninferiority Analysis]Time frame: Baseline, Week 26
Locations
83 sites in 7 countries. Site status is shown where the registry gives one.
John Muir Physician Network Research Center
Concord, California
Valley Research
Fresno, California
Catalina Research Institute, LLC
Montclair, California
Sansum Diabetes Research Institute
Santa Barbara, California
University Clinical Investigators, Inc.
Tustin, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Northeast Research Institute (NERI)
Fleming Island, Florida
Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care
Fort Lauderdale, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Hanson Clinical Research Center
Port Charlotte, Florida
East Coast Institute for Research at The Jones Center
Macon, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Rocky Mountain Clinical Research
Idaho Falls, Idaho
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Cotton O'Neil Clinical Research Center
Topeka, Kansas
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland
Endocrine and Metabolic Consultants
Rockville, Maryland
Clinvest Research LLC
Springfield, Missouri
Palm Research Center Tenaya
Las Vegas, Nevada
Palm Research Center Sunset
Las Vegas, Nevada
Research Foundation of SUNY - University of Buffalo
Buffalo, New York
NYU Langone Hospital - Long Island
Mineola, New York
NYC Research
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Dallas Diabetes Research Center
Dallas, Texas
North Texas Endocrine Center
Dallas, Texas
Research Institute of Dallas
Dallas, Texas
Biopharma Informatic, LLC
Houston, Texas
Amir A Hassan, MD, PA
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas
Rainier Clinical Research Center
Renton, Washington
Instituto Médico Especializado (IME)
Buenos Aires, Argentina
Centro Diabetológico Dr. Waitman
Córdoba, Argentina
Consultorio de Investigación Clínica EMO SRL
Ciudad Autonoma de Buenos Aire, Buenos Air, Argentina
CIAD Moron
Morón, Buenos Air, Argentina
CEDIC
CABA, Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.